#United States #New York #Securities Fraud #Regeneron Pharmaceuticals

Rosen Law Firm Encourages Regeneron Investors to Act

The Rosen Law Firm, a prominent investor rights legal firm, is inviting individuals who purchased securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023, and October 30, 2024, to consider participating in a significant securities fraud lawsuit. This announcement highlights the upcoming lead plaintiff deadline of March 10, 2025, for those wishing to take a leading role in the case.

Why is This Important?

If you were among the investors who bought Regeneron securities during the outlined period, you might be eligible to receive compensation without incurring any out-of-pocket costs. This is made possible through a contingency fee arrangement, which means you will not pay unless the case is successful.

How to Participate

Interested investors can join by visiting Rosen Legal's registration page or by contacting Phillip Kim, Esq. through a toll-free number at 866-767-3653. Alternatively, you can send an email to [email protected] to gather more information about the class action.

A formal class action lawsuit has already been initiated, and if you desire to serve as a lead plaintiff—acting on behalf of fellow class members—you must file a motion with the court by the deadline. The role of a lead plaintiff is crucial, as it involves directing the litigation process.

The Rosen Law Firm’s Expertise

The Rosen Law Firm stands out in the field of investor rights, with a strong track record in securities class actions and shareholder derivative litigation. The firm has consistently earned recognition for its success, having achieved the largest-ever settlement against a Chinese company at the time, and ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017. They have recovered hundreds of millions for investors over the years, including an impressive $438 million in 2019 alone. The firm’s founding partner, Laurence Rosen, has even been acknowledged as a Titan of Plaintiffs' Bar by law360, further emphasizing their credibility.

Case Details

The lawsuit points out that during the class period, the defendants allegedly made false and misleading statements about Regeneron's practices. Key allegations include:
1. Regeneron reportedly paid credit card fees to distributors in exchange for assurances that prices for customers using credit cards to purchase Eylea, a major product of the company, would not be increased.
2. These financial arrangements artificially lowered the prices for customers employing credit cards, misleadingly inflating Eylea sales figures.
3. The company reportedly understated the Average Sales Price (ASP) communicated to federal bodies, thus violating the False Claims Act and misleading investors about the company's true performance and prospects.

Such revelations have raised concerns among investors, leading to the assertion that they suffered damages when these realities were ultimately disclosed to the market.

Next Steps

For those looking to join the Regeneron class action, it's crucial to act swiftly. The class has yet to be certified, which means until that occurs, you are not represented unless you choose to retain your counsel. However, this does not hinder your ability to share in any potential recovery if you opt to remain an absent class member at this point in time.

Stay updated with important developments by following the Rosen Law Firm on LinkedIn, Twitter, and Facebook. For any inquiries, reach out to Laurence Rosen or Phillip Kim at The Rosen Law Firm.

• ---

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll-Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
Website: www.rosenlegal.com

Attorney Advertising. Prior results do not guarantee a similar outcome.